Lampalizumab (黃斑部水腫·黃斑部病變) :預測·市場分析
Lampalizumab (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023
|出版日期||內容資訊||英文 109 Pages
|Lampalizumab (黃斑部水腫·黃斑部病變) :預測·市場分析 Lampalizumab (Macular Edema and Macular Degeneration) - Forecast and Market Analysis to 2023|
|出版日期: 2014年10月31日||內容資訊: 英文 109 Pages||
Lampalizumab是以補體因子D為標鞄的人體化單株抗體 (人mAb) 之抗原結合性片段。
Macular Edema is a condition where fluid accumulates on the macula, leading to vision impairment or in severe cases even vision loss. The three main types of ME are diabetic macular edema (DME), and macular edema following either a central or branch retinal vein occlusion (ME-CRVO and ME-BRVO). Age-related macular degeneration (AMD) is a painless eye condition which leads to gradual, irreversible, loss of central vision, and is one of the leading causes of blindness among people aged 50 and over in the developed world. Currently the ME and AMD markets are dominated by the use of anti-VEGF monotherapy, however, in recent years, corticosteroid implants have been reaching the ME market which could challenge the stronghold these drugs have in this sector. The AMD market will see the arrival of the first therapies to treat dry AMD, fulfilling a huge unmet need in the management of this retinal disease, and these first-in-class therapies will strongly drive the market growth over the next ten years. The launch of wet AMD adjunctive therapies will also see a significant change in the treatment of AMD patients and have a positive impact on the market growth.
Lampalizumab, also known as anti-factor D (as well as RG7417 by Roche and as FCFD4514S by its subsidiary, Genentech), is an antigen-binding fragment of a humanized mAb that targets complement factor D, the rate-limiting enzyme involved in the activation of the alternative complement pathway.